Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
Ethel Ciampi, Reinaldo Uribe-San-Martín, Bernardita Soler, L. Aybar García, Jorge A. Guzmán, Carolina Pelayo, Lukas Jürgensen, Ignacio Guzman, Francisco Vera‐Sempere, Lorna Galleguillos, Claudia Cárcamo
Topics & Concepts
MedicineVaccinationInactivated vaccineAdverse effectImmunologyMultiple sclerosisGlatiramer acetateFingolimodNatalizumabAlemtuzumabAntibodyTeriflunomideReactogenicityInternal medicineImmunogenicityVirologySARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders